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1. Introduction 
Ferritin is a positive acute phase reactant, exhibiting increased levels in blood during the 
acute phase response. Nevertheless, the precise role of ferritin as an acute phase reactant 
remains to be clarified. As for other acute phase proteins, ferritin is produced and secreted 
by hepatocytes. However, ferritin is also produced and secreted by other cell types, 
including macrophages and cancer cells. Many isoforms of ferritin (isoferritins) are found in 
the body, depending on the H-subunit to L-subunit ratio in the ferritin protein shell. The 
subunit composition of ferritin molecules is a major determinant of the functional properties 
of the ferritin isoforms. Expression of ferritin and its subunits is governed by the amount of 
metabolically available iron, the presence of oxidative stress and both pro- and anti-
inflammatory cytokines. Ferritin as an acute phase reactant is well known for its 
intracellular iron sequestration and storage abilities during immune activation (Weiss & 
Goodnough, 2005). This function is of high importance for protection of the body against 
microbial proliferation, oxidative damage, inflammation and cancer. Although the 
regulation of iron appears to be a primary function of ferritin in both normal conditions and 
during the acute phase response, other functions, beyond the control of iron bio-availability, 
have also been described. Although more investigations are required in order to clarify the 
precise role of ferritin as an acute phase reactant, this chapter shows a synopsis on the 
present knowledge on ferritin during the acute phase response. In the first part of this 
chapter (2-4), the processes of iron sequestration, storage and release by the ferritin 
molecule, the significance of the presence of isoferritins, and the regulation of the expression 
of ferritin by iron are described. In the next section (5) changes with diseases, and possible 
significance of extracellular (plasma) ferritin is discussed. In the last section (6-11) the 
differential up-regulation of H-subunit rich ferritins during the acute phase response, the 
importance of H-subunit rich ferritins in the withholding of iron by the macrophage, as well 
as its role in immune modulation, its pro-apoptotic and anti-apoptotic activities, and 
variations in cancer are addressed. 
2. The ferritin molecule: Sequestration, storage and release of iron 
The major functions of intracellular ferritin are the sequestration, storage and release of 
cellular iron. Body iron can be present as either the highly toxic Fe2+-ions or as harmless, 
insoluble Fe3+-ions. Ferritin detoxifies Fe2+-ions by converting them to the insoluble Fe3+-
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ions. Ferritin can accumulate up to 4500 iron atoms as a ferrihydrite mineral in a hollow 
protein shell and releases these iron atoms when there is an increase in the cell’s need for 
bio-available iron. The ferritin molecule consists of an outer three-dimensional protein shell 
with a diameter of 12-13 nm enclosing an inner cavity with a diameter of 7-8 nm. In this 
inner cavity, ferritin is capable of sequestering variable amounts of Fe3+-atoms as a 
ferrihydrite mineral. The ferritin protein shell consists of 24 protein subunits of two types, 
the H-subunit and the L-subunit. These ferritin subunits perform different functions in the 
multi-step mineralization process of iron. Fe2+-ions enter the ferritin cavity through channels 
in the protein shell facilitated by the presence of local iron binding sites. Upon entering the 
shell the Fe2+-ions are oxidized followed by hydrolysis, nucleation and iron core growth. 
Oxidation of the Fe2+-ions is an obligatory first step and is governed by the H-subunit’s 
ferroxidase center which enzymatically oxidizes Fe2+-ions to Fe3+-ions. The subsequent 
hydrolysis and nucleation of the generated Fe3+-compound is brought about by the L-
subunit. The highly mobile Fe3+-monomers are directed to the inner cavity and properly 
placed on the protein shell/mineral interface by the L-subunit resulting in the formation of a 
ferrihydrite mineral core (Figure 1) (Chasteen, 1998; Harrison & Arosio, 1996). 
Two mechanisms are proposed for the release of iron from ferritin. Iron can be either 
released from the intact ferritin molecule or released upon the degradation of the ferritin 
molecule (Aisen, 1991; Deiss, 1983). Two processes are chemically feasible for removing iron 
from the intact ferritin molecule. The first process involves the reduction of Fe3+-ions to Fe2+-
ions followed by chelation of Fe2+-ions, and the second process the direct chelation of Fe3+-
ions (Gálvez et al., 2005; Harrison & Arosio, 1996; Liu et al., 2003). The release of iron from 
ferritin by these processes is aided by reductants and iron chelators. Reductants and 
chelators gain access to the interior of the ferritin molecule through three-fold channels in 
the protein shell. It is suggested that the channels of the ferritin protein shell are dynamic 
and control the access of reductants and chelators, since reductants and chelators too large 
to pass through the channels can under certain conditions gain access to the interior of the 
ferritin molecule (Liu et al., 2003). Chaotropes can increase the access of reductants and 
chelators to the interior of ferritin by influencing the gating of the channel (Gálvez et al., 
2005; Liu et al., 2003). Various reductants and chelators, including physiological and 
toxicological substances, can release iron from ferritin (Agrawal et al., 2001; Gálvez et al., 
2005; Hynes & Coinceanainn, 2002; Sánchez et al., 2005). The hydrous ferric oxide cores can 
be reduced by one electron per iron atom accompanied by an uptake of two protons per 
electron from the surrounding medium (Watt et al., 1985). This is then followed by the 
chelation of Fe2+-ions and the transport to sites where Fe2+-ions are needed (Joshi & 
Clauberg, 1988; Watt et al., 1985). Effective reducing agents for the release of iron from 
ferritin include flavins, cysteine, glutathione, ascorbic acid and superoxide (Ponka et al., 
1998). This mechanism for the release of iron from the intact ferritin molecule can provide 
the cell with iron for metabolic processes. However, the released iron may lead to the 
generation of free radicals that may damage the ferritin molecule itself (Rosseau & 
Puntarulo, 2009). 
In addition to the release of iron from the intact ferritin molecule iron can also be released 
upon the degradation of the ferritin molecule. Two mechanisms are known to be involved in 
the degradation of cytosolic ferritin, i.e., the 20S proteasome enzymatic system in the 
cytosol, and proteolytic enzymes in the lysosomes. The proteolytic enzymes in the 
lysosomes appear to be of greater importance than the cytosolic proteasome enzymatic 
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system for the degradation of ferritin and the subsequent release of iron (Kidane et al., 2006; 
Zhang et al., 2010). Specific iron chelators determine the route of ferritin degradation (De 
Domenico et al., 2009a). Depending on the type of cell, the iron status and whether ferritin is 
degraded free in the cytosol or within a lysosome, different amounts of iron are made 
available for metabolic processes. Degradation of ferritin in the cytosol results in the 
complete release of the iron from ferritin, whereas degradation of ferritin in the 
confinements of a lysosome can result in the entrapment of ferritin iron (Wixom et al., 1980). 
Cytosolic degradation may therefore be the major iron turnover mechanism providing the 
cell with easily accessible iron for shunting into metabolic pathways, while degradation 
within membrane-encapsulated secondary lysosomes, with subsequent haemosiderin 
formation, may prevent the uncontrolled release of iron and may become prominent when 
there is iron overload (Harrison & Arosio, 1996; Wixom et al., 1980). Nevertheless, 
degradation of ferritin in lysosomes can also produce soluble iron, although these larger 
masses of ferritin/haemosiderin may require more time for the release of their iron contents. 
The iron so released would then be translocated back to the cytosol for reutilization in 
metabolic processes or for sequestration by ferritin (Deiss, 1983; Ponka et al., 1998; Radisky 
& Kaplan, 1998). It seems as if the release of iron from lysosomes depends on the magnitude 
of aggregate formation and the subsequent deposition of iron as haemosiderin. 
 
 
Fig. 1. An animated presentation of ferritin molecules with eight subunits – five L-subunits 
in blue, and three H-subunits in red to show the mineralization process of iron by the 
ferritin protein shell. Oxidation of Fe2+ is performed by the ferroxidase centre of the H-
subunit. This is followed by nuclei formation and iron core growth facilitated by L-subunits. 
Once the iron core reaches a sufficient size oxidation of Fe2+ can take place on the surface of 
the iron core. 
3. The ferritin molecule: Isoferritins 
The multiple forms of ferritin have their molecular basis in the ratio of the two types of 
subunits, the H-subunit and the L-subunit. The ferritin protein shell can exist as 
heteropolymers of various combinations of these two types of subunits – a phenomenon that 
gives rise to the existence of isoferritins (Chiancone & Stefanini, 1984). As the roles of the H-
subunit and L-subunit in the mineralization process differ, the subunit composition of 
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ferritin will influence the metabolic properties of the assembled ferritin molecules (Harrison 
& Arosio, 1996; Levi et al., 1994). H-subunit rich ferritins have been shown to accumulate 
and release iron faster than do L-subunit rich ferritins (Arosio et al., 1991; Chiancone & 
Stefanini, 1984; Wagstaff et al., 1982; Worwood, 1990), and it is suggested that the H-subunit 
rich ferritins permit more dynamic intracellular traffic of iron (Chiancone & Stefanini, 1984; 
Speyer & Fielding, 1979). L-subunit rich ferritins apparently contain higher iron amounts 
than the H-subunit rich ferritins (Bomford et al., 1981; Chiancone & Stefanini, 1984), and 
there are indications that the L-subunit rich ferritins predominate in cell types that play a 
role in iron storage (Boyd et al., 1985; Chiancone & Stefanini, 1984; Coccia et al., 1992; Powell 
et al., 1975). It would further appear that a specific subunit composition may support iron 
storage, and that iron loading would increase the expression of the L-subunit upon which 
these L-subunit rich ferritins will sequester the bulk of the iron surplus (Bomford et al., 1981; 
Invernizzi et al., 1990). In general, L-subunit rich ferritins contain 1 500 iron atoms or more, 
whereas H-subunit rich ferritins contain less than a 1 000 iron atoms (Harrison & Arosio, 
1996). In situations of iron overload it may be advantageous to the cell to synthesize L-
subunit rich ferritins, since these ferritins are not only able to store higher iron amounts, but 
can also retain iron more firmly and turn over iron more slowly than their H-subunit rich 
counterparts (White & Munro, 1988). The assumed role that the L-subunit rich ferritins play 
in the sequestration of the surplus iron during iron overload is underlined by the fact that 
their concentration in liver, serum and cultured cells is related to iron levels, whereas the H-
subunit rich ferritins appear either to be non-affected (in liver) or negatively affected (in 
serum) by increases in iron concentrations (Ruggeri et al., 1984). Furthermore, upon iron 
supplementation of patients with functional iron deficiency in the presence of tissue iron 
overload there would appear to be a proportionately greater change in L-subunit rich 
ferritins than in H-subunit rich ferritins (Ruggeri et al., 1984). Due to the H-subunit rich 
ferritin’s more dynamic ability of iron uptake and release it would appear to be largely 
found in cells having high iron requirements for metabolic activities and a non-existent role 
in iron storage (Cazzola et al., 1983). Cells with a high content of H-subunit rich ferritins 
include erythroid cells, heart cells, pancreatic cells, kidney cells, lymphocytes and 
monocytes (Jones et al., 1983; Worwood, 1982), whereas the L-subunit rich ferritins are found 
predominantly in liver and spleen – organs associated with long-term iron storage (Powell et 
al., 1975; Worwood, 1982). The H- to L-subunit ratio of a specific type of cell does, however, 
not remain constant and the proportion of the H- and L-subunits present in the ferritin shell 
changes during differentiation and in various pathological states (Arosio et al., 1976; Boyd et 
al., 1985; Ponka et al., 1998; Theil, 1990). 
4. The ferritin molecule: iron-dependent regulation of the expression of the H-
subunit and L-subunit 
Metabolically available iron is a major determinant of the regulation of ferritin expression. 
In order to accomplish a finely tuned system of ferritin expression as a function of the size of 
the metabolically available iron pool (the labile iron pool) the ferritin gene structure contains 
sequences that sense the size of the labile iron pool (Harford et al., 1994). The 5’-untranslated 
region (5’-UTR) of both the H- and L-subunit mRNA contains a highly conserved 28-base 
sequence known as the iron-responsive element (IRE) sensitive to the metabolically active 
available iron (Worwood, 1990). The IREs are comprised of cis-acting nucleotide sequences. 
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These nucleotide sequences form stem-loop structures that contain a six-membered loop 
with the sequence CAGUGN (Ponka et al., 1998). These stem-loop structures are recognized 
by trans-acting cytosolic RNA-binding proteins required for the coordinated expression of 
the H- and L-subunits (Theil, 1990). These cytosolic RNA-binding proteins, iron-responsive 
protein 1 (IRP1) and iron-responsive protein 2 (IRP2), cause a decrease in H- and L-subunit 
mRNA translation by binding to the stem-loop structures of the 5’-UTR of the respective 
mRNAs. IRP1 and IRP2 mediate the translational efficiency by obscuring the subsequent 
binding of the 43S translation pre-initiation complex needed for the initiation of translation 
(Rogers et al., 1994). Although both the H-subunit and the L–subunit mRNA of ferritin 
contain an IRE, the IREs are regulated differentially. The IRE of the L-subunit mRNA was 
shown to be the primary responder to iron in hypoxic conditions, but this differential 
sensitivity is lost in normoxic conditions (Sammarco et al., 2008). IRP1 and IRP2 both sense 
and homeostatically control the metabolically available iron. For IRP1 this is accomplished 
by the existence of two conformationally distinct forms. IRP1 is a 90 kD iron-sulphur cluster 
protein. When iron is abundant it exists as a cytosolic aconitase. When iron is scarce it 
assumes an open configuration associated with the loss of iron atoms from the iron-sulphur 
cluster and the subsequent binding to the IRE stem-loop structure, acting as a repressor of 
ferritin translation (Torti & Torti, 2002). In contrast, the 105 kD IRP2 protein is regulated by 
degradation: IRP2 protein is abundant in iron scarcity, but is degraded rapidly in iron excess 
through targeting of a unique 73 amino acid sequence and subsequent oxidation and 
ubiquitination (Meyron-Holtz et al., 1999; Torti & Torti, 2002,). This response of ferritin 
synthesis to the size of the metabolically available pool of iron endows the cell with an 
exceptionally rapid mechanism for increasing ferritin synthesis upon iron influx. Iron influx 
increases the labile iron pool and, via binding to IRP1 and IRP2, causes a rapid increase in 
ferritin translation. This rapid response is achieved by a shift of stored mRNA from the 
ribonucleoprotein (RNP) fraction to polysomes (translational shift) (White & Munro, 1988). 
The ferritin response to iron influx can thus be viewed as a protective rapid response 
system, allowing immediate formation of additional ferritin in which to store the surplus 
iron (Truty et al., 2001). Although the H-subunit and L-subunit mRNA shift from the RNP 
fraction to polysomes to the same extent (White & Munro, 1988), the transcription of the L-
subunit gene is preferentially stimulated by an increase in metabolically available iron 
(Worwood, 1990) resulting in an increase in the ratio of L-subunit to H-subunit mRNA, 
which appears first in the RNP fraction and later in the polysomes (White & Munro, 1988). 
This increase in the L-subunit to H-subunit mRNA ratio in the polysomes accounts for the 
change in the ratio of L-subunit to H-subunit protein synthesis following iron 
administration (White & Munro, 1988). Coordinated translational control and differential 
transcriptional control thus exist between these two genes (White & Munro, 1988). 
5. Extracellular ferritin 
Most of the synthesized ferritin remains within the cell where it sequesters and releases iron 
in order to maintain intracellular iron homeostasis. Besides the presence of ferritin in the 
cytosol of the cell, ferritin is also found in smaller quantities in the plasma. It is suggested 
that ferritin may enter the circulation either via secretion of ferritin by cells or through the 
release of ferritin from damaged cells (Worwood, 1990). Both mechanisms probably 
contribute to plasma levels. Ferritin destined for intracellular iron homeostasis is 
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synthesized on free polyribosomes, whereas a small amount of ferritin may be synthesized 
on the rough endoplasmic reticulum for secretion into the plasma (Covell & Worwood, 
1984; Cragg et al., 1981). The range of plasma ferritin in the normal adult varies between 15-
300 µg/l (Covell & Worwood, 1984; Worwood, 1990), and consists mainly of glycosylated L-
subunit rich ferritins containing insignificant amounts of iron, even in conditions of iron 
overload (Covell & Worwood, 1984; Cragg et al., 1981; Jacobs & Worwood, 1975; Ponka et al., 
1998). For instance, while the iron content of ferritin in the liver and spleen could be more 
than 0.2 µg Fe/µg protein in conditions of iron overload, the iron content of plasma ferritin 
may still be as low as 0.02-0.07 µg Fe/µg protein (Worwood et al., 1976). Although the 
function of plasma ferritin is, as yet not completely clear, it is now known that extracellular 
ferritin can act as iron delivery system for ferritin receptor-mediated endocytosis by cells 
(Kalgaonkar & Lonnerdal, 2009; Leimberg et al., 2008; Sibile et al., 1988). Extracellular ferritin 
has further been implicated in functions such as immune modulation, the regulation of 
myelopoiesis, as well as in the regulation of blood vessel formation, and modulation of 
bradykinin release and others (De Domenico et al., 2009b; Parthasara et al., 2002). 
The concentration of ferritin in plasma is a function of the rate of secretion or release from 
cells and the clearance by other cells (Hershko & Konijn, 1984). The major cell type 
responsible for the clearance of plasma ferritins is the hepatocyte. A specific receptor for 
both glycosylated and non-glycosylated ferritin has been demonstrated on the hepatocyte 
membrane (Hershko & Konijn, 1984). These receptors bind both the H-subunit and the L-
subunit of ferritin (Halliday et al., 1979). However, a significant difference is indicated 
between the rates of clearance for the non-glycosylated ferritin of tissues, and the 
glycosylated plasma ferritin (Hershko & Konijn, 1984). These differences in clearance may 
result in a significantly longer half-life for the glycosylated, secreted ferritins in the 
circulation compared to that of the non-glycosylated tissue ferritins (Bellotti et al., 1987; 
Halliday et al., 1979; Hershko & Konijn, 1984; Worwood, 1990). The scavenger receptor 
(receptors that bind various ligands) SCARA5, has recently been identified as a cell surface 
receptor that preferentially binds to L-subunit rich ferritins followed by internalization (Li et 
al., 2009). The clearance of ferritin may, however, also be influenced by the interaction 
between ferritin and other plasma components such as plasma proteins, ferritin-immune 
complexes and ferritin auto-antibodies. Of particular interest is the fact that α-2-
macroglobulin has been identified as a ferritin binding protein (Massover, 1994). Alpha-2-
macroglobulin-binding is known to augment the clearance of substances from the 
circulation. 
Under normal conditions a quantitative relationship exists between the level of plasma 
ferritin and the amount of storage iron (Cazzola & Ascari, 1986). In conditions of iron 
overload there is generally an increase in the expression of intracellular L-subunit rich 
ferritins, paralleled by an increase in these ferritins in the plasma (Halliday & Powell, 1979). 
Although the specific cellular origin of plasma ferritin is not known (Torti & Torti, 1994), 
various experiments indicated a large contribution made by the reticulo-endothelial cells. 
An increase in plasma ferritin levels is known to occur in parallel with the increase in 
reticulo-endothelial cell ferritin after an increase in reticulo-endothelial cell iron during 
phagocytosis of non-viable red blood cells (Finch et al., 1984; Jacobs & Worwood, 1975). 
However, elevated plasma ferritin levels are also seen in patients with parenchymal iron 
overload whose reticulo-endothelial cells are virtually devoid of iron (Finch et al., 1984). 
Serum ferritin levels are determined in the clinic as part of iron studies and low ferritin 
levels in anaemic patients are generally considered indicative of iron deficiency anaemia 
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(Guyatt et al., 1990). However, to use ferritin as a measure of body iron in the presence of 
inflammatory conditions woud lead to erroneous underestimation of the degree of iron 
deficiency. The reason for this is probably that although iron is a major trigger for the 
synthesis of ferritin, cytokines would appear to take over the central role in the regulation of 
ferritin synthesis during inflammatory conditions (Feelders et al., 1998). The cytokines 
involved in stimulation of ferritin synthesis are mainly of a pro-inflammatory nature and it 
is known that pro-inflammatory cytokine activity forms an integral part of the acute phase 
response. For the detection of iron deficiency in the presence of inflammation, several ways 
of correcting measured ferritin levels for the effect of inflammation have been suggested, 
amongst others by the World Health Organization (WHO, 2004 & 2007). Inflammation may, 
however, be present at subclinical levels, yet influence the ferritin levels. In a meta-analysis, 
examining the adjustment of plasma ferritin concentrations to compensate for the effects of 
subclinical inflammation in the assessment of iron deficiency, Thurnham et al. (Thurnham et 
al., 2010) found the simultaneous measurement of C-reactive protein and α1-acidic 
glycoprotein to be a good estimate of the full effect of inflammation for the correction of 
ferritin levels. 
Plasma ferritin concentration is affected by a number of factors other than the amount of 
storage iron and inflammatory activity. Other conditions known to influence plasma ferritin 
levels include tissue necrosis, damage to ferritin-rich tissue, infections, neoplastic disease, 
increased red blood cell turnover, malnutrition as in anorexia nervosa and surgery (Cazzola 
& Ascari, 1986; Hershko & Konijn, 1984; Kennedy et al., 2004; Rubin et al., 1984; Torti & Torti, 
1994; Worwood, 1982). When any of these conditions are present, the relationship between 
plasma ferritin concentration and amount of storage iron no longer holds. With tissue 
necrosis, as in hepatocellular injury, the increase in plasma ferritin is, for instance, due to the 
release of ferritin from the damaged cells, since the increase in ferritin is dependent on both 
the magnitude of cellular damage and liver iron stores (Halliday & Powell, 1979). 
Furthermore, an increase in non-glycosylated, iron-rich ferritins has been reported upon 
tissue damage, which is indicative of the release of ferritin from damaged tissue, rather than 
an increase due to active secretion (Cragg et al., 1981). 
Neoplastic diseases are in general accompanied by raised levels of ferritin in the plasma. It is 
suggested that the increase in plasma ferritin may be related to an increased production of 
ferritin by the malignant cells. In leukemia the normal concentration of ferritin in circulating 
leukocytes is increased up to six-fold in acute myeloblastic leukemia, more than twenty-fold 
in acute myelomonocytic leukemia, and two- to three-fold in chronic granulocytic leukemia 
(Jacobs & Worwood, 1975). In the presence of various solid tumours, including tumours of 
the breast, pancreas and liver, an increase of H-subunit rich ferritins was shown in the cells 
of the tumours, as well as an increase in plasma ferritin. In addition, the plasma ferritins 
reflected the increase in H-subunit rich ferritins of the tumours. Therefore the tumours seem 
to produce and secrete these H-subunit rich ferritins (Kew et al., 1978; Niitsu et al., 1984). 
This assumption, that the raised ferritin levels seen in a number of malignancies are the 
result of secretion from the malignant cells, does, however, not exclude the possibility of a 
further augmentation of plasma ferritin levels through cancer-related cytokine activity. 
Raised levels of plasma ferritin have also been reported for Still’s disease – a systemic 
inflammatory disorder (Evenson et al., 2007), the haemophagocytic syndrome – a disorder 
strongly associated with autoimmunity (Sekigawa et al., 2001), and in patients at risk for 
coronary artery disease and myocardial infarction (De Godoy et al., 2007). Low serum levels 
of ferritin were seen in neurological disorders such as neuroferritinopathy – a disorder of 
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the basal ganglia, (Levi et al., 2005), in restless legs syndrome (Kotagal & Silber, 2004), and in 
neurally-mediated syncopy in children and adolescents (Jarjour & Jarjour, 2008). Plasma 
ferritin in these conditions would therefore not be a good indicator of iron stores. 
Ferritin levels have, on occasion, been described as a biomarker for a number of pathologies 
(Goswami et al., 2009). Suggestions are that raised levels of ferritin can be used as biomarker 
for pathological conditions such as artherosclerosis, certain types of cancer, diabetes mellitus 
2, a number of pregnancy complications, foetal growth restriction and others (Goswami et 
al., 2009; Hou et al., 2000). Although increases in serum ferritin due to inherited disorders, 
such as haemochromatosis, porphyria, hereditary hyperferritinaemia-cataract syndrome 
(Kato & Niitsu, 2002), and certain neurological diseases can occur, increases are generally 
not disease specific. The value of a raised ferritin level as differential diagnostic marker is 
therefore relatively limited as it is feasible to assume that the increased levels would 
predominantly be secondary to activities such as altered iron metabolism, oxidative stress, 
inflammatory processes and, in a small number of conditions, abnormal synthesis or 
clearance. Nevertheless, the determination of ferritin levels has been reported to have a role 
in the assessment of disease progression in conditions such as cancer, liver failure, acquired 
iron overload, multiple trauma, after organ transplantation, in acute and chronic 
inflammatory conditions and other (Wang et al., 2010). In addition to the identification of 
iron deficiency in otherwise normal individuals, and of iron overload, ferritin levels thus 
appear to be of clinical value in the assessment of prognosis and disease progression of 
certain disorders. Abnormal ferritin levels in the absence of abnormal total body iron may 
warrant further investigation. Although the value of ferritin as a reflection of body iron 
stores may be compromised during the acute phase response, the potential exists for ferritin 
as indicator of disease progression. 
6. Acute phase response, inflammatory response and ferritin 
The acute phase response is a systemic reaction to local or systemic infection, tissue damage, 
cancer and in general, immune disturbances. It is a non-specific, early defense system (Cray 
et al., 2009), and can therefore be seen as part of the innate immune system. The acute phase 
response is induced in the liver and also in various other tissues, and consists of both 
intracellular and extracellular acute phase proteins (Tilg et al., 1997). The inflammatory 
response, with the associated production of cytokines, forms an integral part of the acute 
phase response. Cytokines, both pro-inflammatory and anti-inflammatory, take part in the 
regulation of the production of the acute phase proteins, and mediate an increase in the so-
called positive acute phase proteins and a decrease in the so-called negative acute phase 
proteins. Cytokines shown to modulate the production of acute phase proteins include the 
pro-inflammatory cytokines interleukin-1β (Il-1β) and interleukin-6 (Il-6), (Ramadori & 
Christ, 1999), and the anti-inflammatory cytokine interleukin-10 (Il-10) (El Kasmi et al., 
2006). Up or down transcriptional regulation provides the necessary control for the 
synthesis of the acute phase proteins. One of the transcription factors involved in the 
synthesis of the acute phase proteins, signal transducer and activator of transcription 3 
(stat3), originally named acute phase response factor (APRF), regulates the response to both 
pro- and anti-inflammatory cytokines (Desiderio & Yoo, 2003; Turkson & Jove, 2000). 
Ferritin is considered a positive acute phase protein and is up-regulated intracellularly in 
many cell types, and extracellularly, in the plasma as a result of an increase in cellular 
secretion. An important role for ferritin during the acute phase response is to restrict the 
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availability of iron by sequestration into the cavity of the ferritin protein shell. Furthermore, 
ferritin can modulate many immune functions, play a role in pro-apoptotic and anti-
apoptotic pathways, and is implicated in the pathology of cancer. 
Oxygen radicals, i.e., molecules containing unpaired electrons are generated in large 
amounts during infectious and inflammatory conditions (Di Virgilio, 2004). They react with 
proteins, lipids and nucleic acids, resulting in degradation of the phagocytosed material in 
the confinements of the phagosome in the neutrophil and macrophage. However, large 
amounts of these toxic metabolites leak to the fluids and tissues in the area of the 
inflammatory reaction and by reacting with cellular constituents can result in substantial 
damage (Closa & Folch-Puy, 2004; Liu & Pope, 2004). Iron, due to its role in Fenton-type 
chemistry, can result in exacerbation of oxygen radical production. Such an increase in 
unwanted oxygen radical production due to toxic amounts of iron can be seen in chronic 
inflammatory conditions. An increase in the iron content in the synovium is, for instance, 
present in rheumatoid arthritis (Giordano et al., 1991), and a significant correlation exists 
between thiobarbituric acid-reactive material (lipid peroxidation product), the amount of 
iron in the synovial fluid, and the inflammatory activity of the disease (Rowley et al., 1984). 
Furthermore, when anaemic rheumatoid arthritis patients receive iron supplementation, 
lipid peroxidation is stimulated resulting in worsening of the synovial inflammation (Blake 
et al., 1985). 
In general, a reduction in the bio-availability of iron will offer protection against cell injury 
by hydroxyl radicals that are generated from neutrophil- and macrophage-derived 
superoxides (Rogers et al., 1990). Iron sequestration by cells in the zone of inflammation may 
therefore provide protection against the free radical assault (Rogers et al., 1994). This role of 
host cell protection against an increase in the free radical onslaught is consistent with 
observations that a reduction in ferritin sensitizes cells to pro-oxidant cytotoxicity, and that 
overexpression of ferritin reduces reactive oxidant species (ROS) in cells challenged by 
oxidants and by implication reduces the oxidative toxicity (Torti & Torti, 1994). 
Macrophages, although contributing to the production of ROS, can also provide protection 
against it by reducing the available iron. 
The restriction of bio-available iron during infections and inflammation controls the 
production of reactive oxygen species. In addition, with-holding of bio-available iron from 
micro-organisms can restrict their proliferation and spreading during infections. Most 
micro-organisms need a substantial amount of iron to ensure their survival and are 
endowed with various mechanisms and molecules to obtain iron from host ferroproteins 
such as haemoglobin, ferritin and transferrin (Ganz, 2009). For infections, such as 
tuberculosis, increased macrophage iron is associated with more severe infections with 
worse outcomes (Boelaert et al., 2007). Whereas, supplementing with iron can result in 
susceptibilty to malaria infections in areas with endemic malaria (Prentice, 2008). In order to 
suppress the growth of the pathogen the host responds by sequestering iron as evidenced by 
increased ferritin expression in the chronic phase of trypanosomiasis (Stijlemans et al., 2008). 
7. Differential up-regulation of H-subunit rich ferritins during the acute phase 
response 
The overexpression of either the H- or the L- subunit is known to protect against oxidative 
stress (Orino et al., 2001). Nevertheless, the H-subunit rich ferritins have been shown to offer 
better protection than L-subunit rich ferritins. L-subunit rich ferritins predominate in cell 
types that play a role in the storage of iron (Boyd et al., 1985; Chiancone & Stefanini, 1984; 
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Powell et al., 1975), and there are indications that L-subunit rich ferritins contain more iron 
than those ferritins rich in H-subunits (Bomford et al., 1981; Chiancone & Stefanini, 1984). 
However, rapid sequestration of iron is called for in inflammation to protect cells against the 
unwanted accumulation of reactive oxygen species that could damage various cellular 
components. H-subunit rich ferritins have been shown to accumulate and release iron faster 
than L-subunit rich ferritins (Arosio et al., 1991; Chiancone & Stefanini, 1984; Wagstaff et al., 
1982; Worwood, 1990), and it is suggested that the H-subunit rich ferritins permit a more 
dynamic intracellular traffic of iron than L-subunit rich ferritins (Chiancone & Stefanini, 
1984; Speyer & Fielding, 1979). It is generally assumed that H-subunit rich ferritins are also 
responsible for the rapid sequestration of iron in situations where iron can contribute to 
damage to the cell (Arosio & Levi, 2002), and that an increase in the expression of the H-
subunit rich ferritins protects the cell against oxidative stress by attenuating the production 
of hydroxyl radicals by the Fenton reaction (Cozzi et al., 2000; Zhao et al., 2006). The 
induction of H-subunit rich ferritins in vivo results in a phenotype of tissue-specific iron 
depletion. H-subunit rich ferritins can act as a potent regulator of iron metabolism in tissues 
and these effects can dominate normal iron homeostatic mechanisms (Wilkinson et al., 2006). 
However, cells can limit the accumulation of H-subunits by differentially secreting H-
subunits in variance with L-subunits. Such a mechanism could play a significant role in 
regulating the amount of cytosolic H-subunit rich ferritin and might protect the cell against 
unwarranted rapid sequestration of iron by H-subunit rich ferritins (Goralska et al., 2003). 
Cytokines, central mediators of the inflammatory activity of the acute phase response, have 
been shown to up-regulate the expression of ferritin (Konijn & Hershko, 1977; Piñero et al., 
2000). Pro-inflammatory cytokines reported to have the ability to induce ferritin expression 
include Il-1α, Il-1β, Il-2, Il-6, tumour necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) 
(Miller et al., 1991; Pang et al., 1996; Rogers et al., 1990; Rogers, 1996; Stites et al., 1999; Torti & 
Torti, 2002). These cytokines modulate ferritin expression by both transcriptional and 
translational mechanisms (Piñero et al., 2000), but largely by an increase in the rate of 
transcription of the ferritin genes (Miller et al., 1991; Torti & Torti, 2002). Furthermore, 
cytokines differentially regulate the expression of the ferritin subunits, and it is mostly the 
H-subunit of ferritin that is increased by cytokine induction at variance with the L-subunit 
(Miller et al., 1991; Pang et al., 1996; Rogers, 1996; Stites et al., 1999; Torti & Torti, 2002). 
Cytokines can also up-regulate the expression of ferritin by stimulating the production of 
reactive oxygen species. Pro-inflammatory cytokines increase the production of reactive 
oxygen species in various ways (Gougerot-Pocidalo et al., 2002; Yang et al., 2007). 
Furthermore, free oxygen radicals can, in turn, mediate signal transduction pathways that 
induce cytokine production and anti-oxidants have been shown to inhibit this 
transcriptional increase in the production of inflammatory cytokines (Ali et al., 1999; 
Blackwell et al., 1996; Dröge, 2002; Kosmidou et al., 2002; Tapia et al., 2003). An increase in 
oxidative stress is known to result in the transcriptional up-regulation of ferritin. This is part 
of a cellular anti-oxidant response induced by pro-oxidants to provide protection against 
reactive oxygen species. Induction of transcription is governed by the anti-oxidant 
responsive element (ARE) present in the ferritin genes upstream to the transcription 
initiation site. The H-subunit and the L-subunit genes both contain AREs, but at different 
positions upstream from the transcription initiation site and more importantly these AREs 
are regulated differentially (Hintze & Theil, 2005; Iwasaki & MacKenzie, 2006; Torti & Torti, 
1994). Damage to mitochondria with the consequent increase in iron-mediated reactive 
oxygen radical accumulation resulted in the preferential transcription of the H-subunit of 
ferritin governed by the ARE of the H-subunit’s gene (MacKenzie et al., 2008). In addition, 
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oxidants can also up-regulate the expresion of ferritin through their influence on IRP1 (Cairo 
et al., 1996; Orino et al., 2001; Tsuji et al., 2000), and by releasing iron from cellular proteins 
(Cairo et al., 1995). 
8. The macrophage, iron metabolism and H-subunit rich ferritins during the 
acute phase response 
The macrophage is central to the decrease in plasma iron that is associated with immune 
activation. This hypoferraemic state is predominantly orchestrated by cytokines. Various 
iron homeostatic processes are affected by these cytokines with the combined actions 
resulting in entrapment of iron in the macrophage and a decrease in serum iron. This 
process is known as the iron transfer block (Weiss & Goodnough, 2005). The so-called iron 
transfer block is generally associated with chronic inflammatory conditions. Inflammation, 
mediated by cytokines, produces a shift in iron handling by the macrophage in favour of 
iron storage, in time leading to hypoferraemia (Alvarez-Hernández et al., 1989; Fahmy & 
Young, 1993; Worwood, 1990), haemosiderosis of the macrophage (Finch et al., 1984; 
Lipschitz et al., 1971; Worwood, 1990), and the anaemia of chronic disease (Weiss & 
Goodnough, 2005). The latter is, however, only partly due to a decrease in iron available for 
haemotopoiesis as factors such as suppression of the proliferation of erythroid progenitor 
cells, a decrease in the synthesis of erythropoietin, a decrease in the sensitivity of 
erythroblasts to erythropoietin and a decrease in the red blood cell life span, contribute 
(Weiss & Goodnough, 2005). Ferritin plays a major part in the establishment and 
maintenance of an iron transfer block and thus in the hypoferraemic state of the 
inflammatory reaction. TNF-α, Il-1β, Il-6 and Il-10 have all been shown to directly stimulate 
the transcription and translation of ferritin (Ludwiczek et al., 2003; Weiss & Goodnough, 
2005). Activation of macrophages by cytokines such as, TNF-α and Il-1, results in the slower 
release of iron compared to non-stimulated macrophages, thus supporting the proposed role 
of cytokines in ferritin-mediated iron sequestration by macrophages (Alvarez-Hernández et 
al., 1986; Savarino et al., 1999). However, other iron homeostasis proteins also contribute to 
the reduction in serum iron. Most proteins involved in the acquisition, storage and release of 
iron are influenced, to different extents and at different time-points during the inflammatory 
reaction, by cytokines. With an inflammatory reaction the cytokine Il-6 has, for instance, 
been shown to stimulate the hepatic expression of the acute phase protein hepcidin. 
Hepcidin, in turn, inhibits duodenal absorption of iron by down-regulating ferroportin 
expression thus reducing serum iron (Ganz, 2004). IFN-γ, by increasing the expression of the 
divalent metal transporter 1, has been shown to stimulate the uptake of ferrous iron by 
macrophages. Not only pro-inflammatory, but also anti-inflammatory cytokines are 
involved in the establishment of an iron transfer block. It has, for instance, been shown that 
Il-4 and Il-10 can up-regulate transferrin receptor expression, resulting in an increase in 
transferrin receptor-mediated uptake of iron by the macrophage (Ludwiczek et al., 2003; 
Weiss & Goodnough, 2005). Furthermore, an increase in the phagocytosis and degradation 
of senescent erythrocytes is known to occur with an inflammatory reaction. This process is 
directly up-regulated by TNF-α stimulation as a result of the increase in the expression of 
C3bi (CD11b/CD18) receptors responsible for the recognition and uptake of damaged 
erythrocytes. In addition, TNF-α can indirectly up-regulate this process by damaging 
circulating erythrocytes. These damaged erythrocytes are then phagocytosed upon binding 
to C3bi (CD11b/CD18) receptors followed by degradation (Ludwiczek et al., 2003; Weiss & 
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Goodnough, 2005). Not only is haemoglobin iron obtained by degradation of red blood cells, 
but free plasma haemoglobin is taken up by the haemoglobin scavenger receptor, CD163. Il-
10 and Il-6 contribute to macrophage haemoglobin acquisition by stimulating the expression 
of the haemoglobin scavenger receptor, CD163 (Ludwiczek et al., 2003). INF-γ, down-
regulates the expression of ferroportin, the major transmembrane protein responsible for the 
release of macrophage iron, thus inhibiting iron export from macrophages (Ludwiczek et al., 
2003), a process that is also affected by hepcidin (Deicher & Hörl, 2006). Down-regulation of 
ferroportin occurs only later in the inflammatory response after the onset of hypoferraemia. 
It is therefore suggested that the down-regulation of ferroportin is not responsible for the 
development of the iron transfer block, but that it plays a major role in the maintenance of 
the iron transfer block (Ludwiczek et al., 2003). Many of the pro-inflammatory mediated 
effects on iron homeostasis are counterbalanced by anti-inflammatory cytokines such as IL-4 
and IL-13 (Ludwiczek et al., 2003). 
The abnormal retention of iron by the macrophage, due to an increase of ferritin synthesis, 
has long been seen as a non-specific acute phase reactant of inflammation (Konijn & 
Hershko, 1977; Worwood, 1990). The increase in ferritin synthesis occurs prior to the 
reduction of serum iron levels and is considered to result in a diversion of iron from the 
intracellular labile iron pool to ferritin, and subsequently to haemosiderin (Alvarez-
Hernández et al., 1986; Fillet et al., 1989; Jurado, 1997; Torrance et al., 1978; Worwood, 1990). 
The increase in ferritin expression by the macrophage mostly influences the early phase of 
iron release. In normal conditions two-thirds of the iron entering the macrophage/reticulo-
endothelial system (RES) is released during this phase, but an increase in ferritin expression 
can result in a decrease in the release of iron during this phase to only 10% of the iron 
entering the macrophage/RES (Fillet et al., 1974; Torrance et al., 1978). However, the slow 
release phase of iron from the macrophage is also influenced and can result in a situation 
where 33% of the iron is still present in storage form in the macrophage/RES after 60 days 
(Noyes et al., 1960). Furthermore, once the macrophage and other macrophage-like cells 
have been activated, as occurs during inflammation, these cells express increased levels of 
transferrin receptors (Fahmy & Young, 1993), and are therefore able to acquire increased 
amounts of iron by endocytosis of the iron-transferrin-transferrin receptor complex. The 
increase in iron uptake via this route will contribute to the high magnitude of iron 
sequestration and to the ensuing haemosiderosis of macrophages and other macrophage-
like cells. These iron-withholding mechanisms are implemented as a defense strategy in 
order to deplete biologically active iron in the zone of inflammation or, once the 
inflammatory response cannot be contained, systemically (Fuchs et al., 1993). 
Haemosiderin formation can also aid in protection against iron toxicity. Haemosiderin is 
derived from ferritin as a result of degradation of the ferritin protein shell in secondary 
lysosomes (Finch et al., 1984; Fischbach et al., 1971; Ford et al., 1984). Evidence for this is 
found in observations that haemosiderin contains various amounts of degraded ferritin, as 
well as aggregated dense particles of irregular shape with diameters ranging from 10-75 Å, 
which ultrastructurally resemble iron cores (Ringeling et al., 1989, Wixom et al., 1980), and 
that haemosiderin granules are recognised by anti-ferritin antibodies (Harrison & Arosio, 
1996). Ferritin is frequently found in secondary lysosomes and autophagosomes of normal 
cells, such as hepatocytes and macrophages, but its quantity in these organelles increases 
greatly after loading with iron (Richter, 1978) – demonstrating the protective function of 
haemosiderin formation against the toxicity of iron. Ferritin finds its way into lysosomes by 
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autophagocytosis and/or fusion of ferritin clusters with the lysosomal membrane. 
Autophagocytosis is responsible for the turnover of cellular constituents including cellular 
proteins and involves the formation of autophagic vacuoles by invagination of 
intracytoplasmic membranes enclosing a relatively large volume of cytoplasm, together 
with various cellular constituents (Wixom et al., 1980). The autophagic vacuole receives 
digestive enzymes by fusion with a primary or secondary lysosome and becomes an 
autophagosome (Wixom et al., 1980). Within this lysosomal organelle the ferritin protein 
shell is degraded by the action of lysosomal proteases (Richter, 1984). It is suggested that the 
polymerization of ferritin (formation of oligomers of ferritin), which results in a change in 
solubility, heat stability and surface charge, may predispose ferritin to incorporation into 
lysosomes and transformation into haemosiderin (Chiancone & Stefanini, 1984; Ringeling et 
al., 1989). Only once the ferritin protein shell has been modified, most probably by 
denaturation, resulting in the formation of insoluble ferritin molecules, does proteolytic 
decomposition of the ferritin protein shell by lysosomal enzymes take place (Richter, 1984). 
However, not all ferritin molecules in these lysosomal organelles are susceptible to the 
action of lysosomal proteases. Degradation of the ferritin protein shell results in the 
exposure of the iron oxyhydroxide mineral cores followed by aggregation of these 
oxyhydroxide particles and the formation of insoluble masses of iron oxyhydroxide 
(haemosiderin) (Fischbach et al., 1971; Richter, 1978; Weir et al., 1985). Although the main 
purpose of the formation of haemosiderin would appear to be protection against iron 
overload, these larger masses of ferritin/haemosiderin can, at a much slower rate, also 
release iron. This iron is then translocated back to the cytosol for reutilization in metabolic 
processes or for sequestration by ferritin (Deiss, 1983; Ponka et al., 1998; Radisky & Kaplan, 
1998). Haemosiderin is, however, not necessarily the end product as massive quantities of 
iron oxyhydroxide (haemosiderin) from these secondary lysosomes, can accumulate to form 
cytoplasmic organelles known as siderosomes (Richter, 1978). The haemosiderin-containing 
siderosomes can thus be regarded as the end-product of secondary lysosome action in 
which the wall of the original secondary lysosome now encapsulates the digested ferritin 
iron cores (Harrison & Arosio, 1996; Wixom et al., 1980) – although clusters of electron-dense 
material without membranes or only partially enclosed membranes can also occur (Deiss, 
1983; Harrison & Arosio, 1996; Iancu, 1982). Within siderosomes, ferritin can be identified as 
individual particles, in clusters, in paracrystalline hexagonal arrays, or in circular 
arrangements (Iancu, 1992). In cells with marked iron overload, solitary siderosomes seem 
to fuse and to form larger bodies described as “compound siderosomes” (Iancu, 1992). 
The formation of haemosiderin in reticulo-endothelial cells and other macrophage-like cells 
is influenced by inflammatory and infectious conditions. Macrophages subjected to 
increased oxidative stress also degrade ferritin faster than macrophages not challenged with 
an increase in the production of reactive oxygen species (Mehlhase et al., 2005). It is 
therefore, suggested that during inflammatory and infectious conditions the proportion of 
poorly accessible (non-chelatable) iron associated with ferritin similarly increases, 
suggesting a pathway from non-ferritin iron to loosely associated ferritin iron to a well-
sequestered non-chelatable form existing as haemosiderin (Fahmy & Young, 1993). 
Cytokines such as TNF-α and IFN-γ may be responsible for these effects during 
inflammatory and infectious conditions. These cytokines may increase lysosomal activity 
resulting in increased degradation of intracellular ferritin, leading to the formation of 
haemosiderin, from which iron would be less easily liberated for subsequent extracellular 
release (Alvarez-Hernández et al., 1989). In vitro incubation of cells with either TNF-α or 
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IFN-γ increases the expression of ferritin H-subunit mRNA, but not L-subunit mRNA 
(Fahmy & Young, 1993). Such a differential regulation of ferritin subunit expression might 
result in increased amounts of haemosiderin formation, since H-subunit rich ferritins are 
more susceptible to lysosomal degradation. 
H-subunit rich ferritins have indeed been shown to play a role in the iron redistribution 
during inflammation, and also in the iron redistribution of the acute phase response. It has, 
as mentioned before, been reported that H-subunit rich ferritins turnover more rapidly than 
L-subunit rich ferritins (Boyd et al., 1985; Truty et al., 2001; Worwood, 1982). Haemosiderin, 
which contains the degraded ferritin molecules as a result of the lysosomal breakdown of 
ferritin, shows the predominance of denatured subunits to be of the H-subunit type 
(Miyazaki et al., 2002; Ruggeri et al., 1992). A mechanism may therefore exist for 
preferentially directing ferritins rich in the H-subunit into lysosomes which would result in 
the formation of haemosiderin containing a high proportion of denatured H-subunits. It is 
already known that a too great proportion of H-subunits in the ferritin protein shell results 
in ferritin aggregation (Harrison & Arosio, 1996). This may be due to the inadequacy of the 
ferritin protein shell to retain the formed Fe3+-ions resulting in the loss of Fe3+-ions and 
hydrolysis of Fe3+-ions on the outside of the ferritin molecule (Harrison & Arosio, 1996), 
which may be the signal for ferritin to be incorporated into lysosomes. Once inside the 
lysosome the presence of a large number of H-subunits in the ferritin protein shell increases 
the chances of degradation (Bomford et al., 1981), since H-subunit rich ferritins, during 
denaturing conditions, are less stable than L-subunit rich ferritins (Kim et al., 2001; Miyazaki 
et al., 2002). The salt-bridge present in the L-subunit appears to be important for the 
differences in stabilities between H-subunit rich ferritins and L-subunit rich ferritins (Arosio 
et al., 1991). Futhermore, H-subunit rich ferritins are more susceptible to proteolysis due to 
less ordered secondary structures (Bomford et al., 1981). In particular the loop L becomes 
more exposed and/or less immobilized when the proportion of H-subunits increases and 
therefore more accessible to lysosomal enzymes (Chiancone & Stefanini, 1984). 
9. Immune modulation by secreted H-subunit rich ferritins 
Many functions attributed to H-subunit rich ferritins point to a role for these isoferritins in 
immune modulation, including pro-inflammatory and anti-inflammatory activities. H-
subunit rich ferritins are present in most biologic fluids, but not, or only in low 
concentrations, in plasma (Morikawa et al., 1995). The ferritin present in plasma is mostly L-
subunit rich. However, during certain disease states the concentration of H-subunit rich 
ferritin is increased. At present it would appear that the H-subunit rich ferritins are derived 
mostly from monocytes and macrophages as indicated by the secretion of H-subunit rich 
ferritins from many monocyte-macrophage cell lines, as well as by monocytes from blood 
and bone marrow (Broxmeyer et al., 1984). In a recent study it was shown that murine serum 
ferritin is mainly secreted by macrophages through a non-classical secretion process 
involving secretory lysosomes and not the endoplasmic reticulum (Cohen et al., 2010). The 
release of H-subunit rich ferritins from monocytes appears to be controlled by T-cell subsets, 
where T-helper cells enhance the release and T-suppressor cells suppress the release 
(Worwood, 1990). These effects are most probably brought about by cytokines, since pro-
inflammatory cytokines are known to induce the secretion of ferritin as part of the acute 
phase response. The secretion of ferritin was shown to be stimulated by cytokines in a 
primary human hepatocyte culture where IL-1α and Il-6 induced a transient secretion of 
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ferritin at 24 hours, followed by a decline to baseline, while TNF-α treatment resulted in a 
sustained increase in ferritin secretion (Torti & Torti, 2002). 
H-subunit rich ferritins can suppress various functions of immune cells. H-subunit rich 
ferritins can, for instance, exert inhibitory effects on E-rosette formation of T- lymphocytes 
(CD2 is the surface molecule on T-lymphocytes which facilitates binding to sheep 
erythrocytes and the formation of so-called E-rosettes), suppress the in vitro responses of 
lymphocytes to various mitogens including PHA and con A, inhibit the mixed-lymphocyte 
reaction, inhibit delayed-type hypersensitivity responses, block the access to T-lymphocytes 
by various regulatory factors by occupying the surface of the cells (Hie-won et al., 1984; 
Worwood, 1990), and decrease leukocyte migration (Worwood, 1990). 
Receptors for H-subunit rich ferritins have been found on various T-cell lines, CD4 and CD8 
T-lymphocytes and on CD19 B-lymphocytes, and the expression of H-subunit rich ferritin 
binding sites on these cells appears to be closely and positively linked to their activation and 
proliferation status (Meyron-Holtz et al., 1994; Morikawa et al., 1995). It would therefore 
appear that H-subunit rich ferritins may perhaps act as feedback inhibitors of activation of 
peripheral blood cells. Quiescent circulating lymphocytes, reticulocytes, erythrocytes, and 
monocytes show little expression of the H-subunit rich ferritin receptor, but PHA-
stimulated lymphocytes, erythropoietin-induced burst forming unit (BFU) cells, and 
differentiated macrophages have all been shown to express above average levels of the 
receptor (Halliday et al., 1994), which may result in these cells being more susceptible to 
inhibition by H-subunit rich ferritins. Increased binding of H-subunit rich ferritins to 
peripheral lymphocytes have also been shown to occur in patients with malignant disorders 
and the magnitude of H-subunit rich ferritin binding to lymphocytes was shown to be 
related to the stage of the malignant process (Ciriello et al., 1987). It is postulated that two 
receptor systems exist for the binding and execution of H-subunit rich ferritin’s effects. The 
first receptor system internalizes the bound ferritin. This system is similar to the receptor 
system operating in erythroid precursors. Developing erythroid cells in the bone marrow 
are often found in close proximity to a central “mother” reticulo-endothelial cell which 
supplies ferritin to these developing red blood cell precursors (Deiss, 1983; Jacobs et al., 
1984). This process, known as rhopheocytosis, is a highly regulated pathway for iron 
assimilation by erythroid progenitor cells (Gelvan et al., 1996; Konijn et al., 1994; Meyron-
Holtz et al., 1994). However, a regulatory effect on cell proliferation and maturation occurs, 
whereas in erythroid precursors such a regulatory effect has not been observed (Meyron-
Holtz et al., 1994; Meyron-Holtz et al., 1999). The second receptor system, with a Kd three 
orders of magnitude lower, does not result in the internalization of the bound ferritin 
(Meyron-Holtz et al., 1994; Meyron-Holtz et al., 1999). This suggests a mechanism for the 
regulation of cellular proliferation and maturation by ferritin not involving iron or the 
sequestration of iron. 
Three specific receptors involving binding and internalization of H-subunit rich ferritins 
have been identified recently. The first involves a receptor identical to TIM-2 (member of the 
T-cell immunoglobulin and mucin-domain gene family) that specifically binds extracellular 
H-subunit rich ferritins followed by the internalization of H-subunit rich ferritins, and is 
expressed in B-cells and in non-haematopoietic organs such as the liver and kidney. 
Internalization of the H-subunit rich ferritins resulted in immunosuppression by inhibiting 
T-cell activation (Knickelbein et al., 2006). The second receptor that binds H-subunit rich 
ferritins is transferrin receptor 1. The binding of H-subunit rich ferritins to this receptor 
resulted in entry into endosomes and lysosomes (Li et al., 2010). The third receptor involves 
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the CXCL12 chemokines and their receprtors. It has been shown that H-subunit rich ferritins 
can repress chemokine receptor-mediated signal transduction and migration of lymphocytes 
by binding to the CXCL12 chemokine’s receptor (Li et al., 2006). The CXCL12 chemokines 
have chemotactic and various activating effects that play important roles in T-helper cell 
responses. H-subunit rich ferritins have been found to bind to the CXCL12’s cell surface 
receptors (CXCR4) in the presence of CXCL12. This complex, consisting of CXCL12 and the 
H-subunit rich ferritin together with the receptor, are then internalized by the cell. On the 
inside of the cell the H-subunit rich ferritins are phosphorylated followed by nuclear 
translocation. Furthermore, intracellular H-subunit rich ferritins can repress CXCR4 
activation followed by inhibition of lymphocyte migration (Li et al., 2006). 
Most of the immunomodulatory studies involving H-subunit rich ferritins seem to be of an 
anti-inflammatory nature. However, it was recently shown that H-subunit rich ferritins 
could also activate a pro-inflammatory pathway by an iron-independent mechanism 
(Ruddell et al., 2009). Ruddell et al. observed that hepatic stellate cells, treated with ferritin, 
set in motion a pathway involving phosphatidylinositol 3-kinase (PI3-kinase) 
phosphorylation, protein kinase C zeta and mitogen-activated protein kinase (MAP-kinase) 
activation, resulting in NFκB activation and eventually in increased pro-inflammatory 
activity. Activation of this pro-inflammatory pathway results in the enhanced production of 
various pro-inflammatory mediators including Il-1β, inducible nitric oxide synthase (iNOS), 
the chemokine – regulated on activation normal T-cell expressed and secreted (RANTES), 
inhibitor of κBα and intercellular adhesion molecule 1 (iCAM1) (Ruddell et al., 2009). Based 
on these findings ferritin has been proposed as a pro-inflammatory signal molecule. 
A number of other immune-related effects have been attributed to these H-subunit rich 
plasma ferritins, including the down-regulation of myelopoiesis and regulation of 
angiogenesis (Broxmeyer et al., 1984; De Domenico et al., 2009b). It has specifically been 
shown that H-subunit rich ferritins, but not L-subunit rich ferritins, down-regulate 
myelopoiesis (Broxmeyer et al., 1986), i.e., the growth and development of granulocytes, 
macrophages, erythrocytes, and platelets (Broxmeyer, 1992; Joshi & Clauberg, 1988), both in 
vitro and in vivo. It has been suggested that H-subunit rich ferritins constitute part of a 
normal inhibitory feedback mechanism for the proliferation of granulocyte-macrophage 
colony forming units (CFU-GM), multipotential colony forming units (CFU-GEMM), and 
erythroid burst forming units (BFU-E) (Broxmeyer, 1992; Jacobs et al., 1984). H-subunit rich 
ferritin decreases the proliferation of cells during myelopoiesis by directly affecting these 
progenitor cells (Broxmeyer, 1992). Surface receptors specific for H-subunit rich ferritins 
have been shown on these progenitor cells (Fargion et al., 1988). These effects of H-subunit 
rich ferritins are mediated via the ferroxidase activity of the H-subunits – most probably by 
inducing intracellular iron starvation (Cozzi et al., 2000; Morikawa et al., 1995), since 
addition of iron completely counteracts the inhibitory effects of the H-subunit rich ferritins 
(Broxmeyer et al., 1991). 
10. Pro-apoptotic and anti-apoptotic activity of H-subunit rich ferritins during 
inflammation 
During inflammation the proliferation and apoptosis of specific immune cells determine the 
course of the inflammatory response. H-subunit rich ferritins play a role in both pro-
apoptotic and anti-apoptotic pathways, not only due to its ability to donate or sequester 
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iron, but also by mechanisms not involving iron. During inflammation, an increase in 
reactive oxygen species (ROS) generation by cytokines is shown to be one of the 
mechanisms whereby cytokines induce apoptosis in cells. Tumour necrosis factor-α (TNF-
α), a pro-inflammatory cytokine, is known to induce apoptosis in many cell types during 
inflammation (Sharma & Anker, 2002). The mechanism by which TNF-α brings about an 
accumulation of ROS and apoptosis involves up-regulation of the labile iron pool (Pham et 
al., 2004). This ROS formation induced by TNF-α is mediated by c-Jun N-terminal kinase 1-
dependent (JNK1) ferritin degradation and subsequent elevation in the labile iron pool 
(Antosiewicz et al., 2007). As H-subunit rich ferritins take-up iron faster and release iron 
faster than L-subunit rich ferritins it can donate or sequester iron resulting in an increase or 
decrease in ROS generation. In cells devoid of H-subunit rich ferritins (reduction of 
intracellular iron storage caused by less H-subunit rich ferritins) TNF-α can not bring about 
an increase in the labile iron pool, the accumulation of ROS and apoptosis. However, when 
TNF-α activation is accompanied by an increase in the expression of H-subunit rich ferritins, 
apoptosis is prevented by the sequestration of iron and the subsequent decrease in ROS 
production (Xie et al., 2005). Thus H-subunit rich ferritins can antagonize this cytokine-
induced apoptosis by sequestration of iron, preventing reactive oxygen species 
accumulation (Vardhan et al, 2010). It has been found that H-subunit rich ferritin expression 
is induced by NF-κB transcription factors. H-subunit rich ferritins prevent sustained c-Jun 
N-terminal kinase cascade activation by TNF-α by reducing the production of ROS achieved 
through iron sequestration (Pham et al., 2004). Not only can H-subunit rich ferritins prevent 
apoptosis by the sequestration of iron, but H-subunit rich ferritins can also cause apoptosis 
by the donation of iron. H-subunit rich ferritins secreted from hepatocytes induce apoptosis 
by the donation of iron to the target cell. H-subunit rich ferritins are released from the 
hepatocyte followed by endocytosis into the target cell. The internalized H–subunit rich 
ferritins increase the level of intracellular iron and support the production of ROS (Bresgen 
et al., 2010). Endocytosis of extracellular H-subunit rich ferritins increases the level of iron, 
promotes Fenton chemistry-based oxidative stress, induces damage to DNA, results in p53 
activation, increases mitochondrial membrane permeability and activates pro-apoptotic Fas 
signalling (Bresgen et al., 2010). 
H-subunit rich ferritins have also been found to take part in the apoptotic events not 
involving iron or its ferroxidase activity. Upon oxidative stress, H-subuint rich ferritins 
increase p53 protein levels and p53 transcriptional activity in a ferroxidase activity-
independent manner (Lee et al., 2009). The gene coding for the H-subunit of ferritin belongs 
to the family of p53-regulated genes. Therefore, p53 activation can bring about an increase in 
H-subunit rich ferritins to support p53 in its apoptotic role (Faniello et al., 2008). 
11. H-subunit rich ferritins and cancer 
High plasma ferritin levels have been reported for various types of cancers, irrespective of 
the amount of total body iron (Aulbert & Scmidt, 1985). It has even been suggested that 
plasma ferritin levels can be used as tumour markers for prognostic purposes and for 
monitoring the activity of certain types of cancer (Aulbert & Steffens, 1990; Silber et al., 
1991). In patients with solid tumours, such as pancreatic carcinoma, lung cancer and 
hepatoma, there is a particularly high incidence of elevated plasma ferritin, and in patients 
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with breast cancer, with metastasis, ferritin plasma concentrations are commonly elevated 
(Worwood, 1982). It is of interest that ferritin levels in breast cancer are not only raised in 
the plasma, but also in breast tissue (Ionescu et al., 2006; Weinstein et al., 1982). Squamous 
cell carcinoma of the head and neck is marked by increased plasma ferritin concentrations, 
which remains high in patients with a poor prognosis in contrast to patients with a 
favourable prognosis (Maxim & Veltri, 1986). The plasma ferritin concentrations of patients 
with haematologic malignancies are well documented. Extremely high plasma ferritin levels 
were seen in acute myeloblastic leukemia whereas in complete remission ferritin plasma 
concentrations returned back to normal (Aulbert & Schmidt, 1985). In Hodgkin’s disease, 
plasma ferritin concentrations are said to be related to the stage of the disease, increasing 
from stage 1 to stage 4 (Worwood, 1982). In non-Hodgkin’s lymphoma a remarkable 
correlation was found between plasma ferritin concentrations and tumour histology. The 
highest plasma ferritin concentrations are said to be found in patients with active histiocytic 
lymphoma and the lowest plasma ferritin concentrations in patients with lymphocytic 
lymphoma whereas intermediate plasma ferritin concentrations are found in patients with 
mixed histology (Worwood, 1982). 
Many factors are suggested to contribute to the hyperferritinaemia associated with cancer, 
including inflammation, hepatic necrosis due to metastasis and chemotherapy, blood 
transfusions and a decrease in hepatic clearance of ferritin (Vernet et al., 1995). In addition, a 
modified and increased synthesis and secretion of ferritin by tumour cells occur (Aulbert & 
Steffens, 1990; Kirkali et al., 1999; Vernet et al., 1995; Yang et al., 2001). In many instances the 
increased ferritin is shown to be H-subunit rich (Bevilacqua et al., 1988; Higgy et al., 1997; 
Jones et al., 1980; Tripathi & Chatterjee, 1996; Vernet et al., 1995; Whittaker et al., 1984), and it 
has been suggested that the measurement of H-subunit rich ferritin may be of value in the 
diagnosis of malignancy (Jones et al., 1980). In a study involving breast cancer patients it has 
been shown that H-subunit mRNA was directly related to axillary lymph node status, the 
presence of metastatic disease and to the clinical stage (Yang et al., 2001). 
The secretion of H-subunit rich ferritins in patients with cancer could be involved in the 
immunosupression seen in these patients. In in vitro studies, melanoma cells have, for 
instance, been found to release H-subunit rich ferritins. These H-subunit rich ferritins were 
able to suppress the response of peripheral blood lymphocytes stimulated by anti-CD3. 
These effects were mediated by the activation of regulatory T-cells to produce Il-10 (Gray et 
al., 2003). Similar indications were seen in patients with melanoma. H-subunit rich, but not 
L-subunit rich ferritins, were found to be elevated in melanoma patients, with the H-subunit 
to L-subunit ratio correlating with the levels of regulatory T-cells (Gray et al., 2003). 
The most common feature of cancer is the abnormal proliferation of cells, either contained in 
a specific location, or following metastasis at different sites involving various organs. Iron is 
a necessary element for cellular proliferation and it is generally accepted that rapidly 
dividing cells require more iron for their growth and metabolism than resting cells, and that 
cells normally display an increase in cellular proliferation upon an increase in the labile iron 
pool (Kakhlon et al., 2001). Malignant cells, because of their higher requirement for iron, are 
very sensitive to iron depletion (Kalinowski et al., 2007). In addition, the cellular labile iron 
pool can modulate the magnitude of cellular proliferation by the oncogene H-ras (Kakhlon 
et al., 2002). It is already known that iron homeostasis is dysregulated in cancerous cells. For 
instance, human breast cancer cells are characterised by substantial alterations in the levels 
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of proteins that are responsible for the maintenance of intracellular iron homeostasis, 
including transferrin, IRP1, IRP2, H-subunit and L-subunit of ferritin (Shpyleva et al., 2011). 
In view of their high need for iron, malignant cells would have mechanisms able to increase 
the labile iron pool. One way in which to bring about an increase in the cellular labile iron 
pool would be by suppression of ferritin synthesis. The transcription factor encoded by the 
proto-oncogene c-MYC, which is responsible for proliferation of normal cells, can during 
uncontrolled expression result in cellular transformation and excessive cellular proliferation. 
c-MYC can, where appropriate, activate or repress target genes in order to bring about 
cellular proliferation (Wu et al., 1999). The expression of the H-subunit gene is shown to be 
down-regulated by c-MYC and to be essential for the control of cellular proliferation and 
transformation by c-MYC (Wu et al., 1999). This is in agreement with the fact that H-subunit 
rich ferritins are responsible for controlling the labile iron pool and that down-regulation of 
H-subunit expression would result in an increase in the labile iron pool. The down-
regulation of intracellular H-subunit rich ferritins has also been shown to be required for the 
pathogenesis of cancer. Epithelial-mesenchymal transition (EMT) contributes to tumour-
invasive phenotypes and metastasis. The down-regulation of H-subunit rich ferritins was 
shown to occur between the early and highly invasive advanced stages in esophageal 
adenocarcinoma (Zhang et al., 2009). It is suggested that an increase in the labile iron pool 
plays a role, since depletion of the labile iron pool and a decrease in ROS suppress the 
migration of tumour cells (Zhang et al., 2009). 
In contrast, up-regulation of intracellular H-subunit rich ferritins has been shown in several 
studies (Elliot et al., 1993; Shpeleva et al., 2011; Weinstein et al., 1982). In the study by Shpeleva 
et al., involving human breast cancer, an increase in the expression of the H-subunit and L-
subunit intracellular levels of ferritin was associated with a decrease in the labile iron pool 
(Shpeleva et al., 2011). This increase in the production of intracellular ferritin, together with an 
increase in the H-subunit rich ferritin in the chromatin-bound nuclear fraction, is postulated to 
be one of the defense mechanisms in cancer cells against iron-induced toxicity. Furthermore, 
the increase in intracellular ferritin production has been associated with the acquisition of a 
metastatic and multi-drug resistant phenotype (Shpeleva et al., 2011). It was also shown that 
down-regulation of the H-subunit of ferritin increased the cancer cell’s sensitivity to the 
chemotherapeutic agent Doxorubicin (Shpeleva et al., 2011). 
At present, many research studies support the concept that an increase in intracellular bio-
available iron can augment the development and progression of cancer. Although low 
intracellular ferritin concentrations, and by implication high intracellular iron levels, could 
favour the proliferation of malignant cells, plasma ferritin levels are generally high in 
patients with cancer. As plasma ferritin is generally a secretory product of cells it is unlikely 
that intracellular ferritin levels would be low in conjunction with excessively high 
extracellular levels. In fact, measurements of tissue ferritin levels showed, in general, 
increased levels of ferritin in malignant breast tissues, at least in advanced more aggressive 
stages (Elliot et al., 1993; Shpeleva et al., 2011; Weinstein et al., 1982). As a rule, one would 
expect these high intracellular ferritin levels to decrease bio-available iron – which is 
contrary to the requirement of cancer cells. The answer to this conundrum is largely still at 
the conjectural stage. Research is necessary to distinguish between observations that reflect 
attempts of malignant cells to create conditions favourable for proliferation and those of the 
body to protect against such proliferation. What we do know is that iron metabolism is 
dysregulated in cancer, and that changes occur in both intracellular and extracellular ferritin 
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pools. Although some work exists on the redistribution of ferritin and iron, the type of 
ferritin, as well as the cancer phenotype and stage of malignancy (Cade et al., 1998; Kabat & 
Rohan, 2007; Rossiello et al., 1984; Shpeleva et al., 2011; Wu et al., 2004), more studies are 
urgently needed. 
12. Conclusion 
Up-regulation of ferritin during the acute phase response protects against microbial growth, 
oxidative damage, and is involved in the regulation of immunological activity, apoptotic 
processes and cellular proliferation. During most of these activities the H-subunit of ferritin 
is differentially up-regulated, and appears to play a more important role than the L-subunit 
in establishing ferritin’s functional properties during the acute phase response. 
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